Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-nCoV/O and Ad5-nCoV/O-IH Booster in mRNA-Primed Adults
NCT05442684Phase 3Withdrawn
- Sponsor
- CanSino Biologics Inc.
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of Ad5-nCoV/O in coronavirus disease 2019 (COVID-19), sponsored by CanSino Biologics Inc.. Planned start Nov 2022; status: withdrawn.
02
Drugs
Ad5-nCoV/O
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05442684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442684.